Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis

IntroductionNon-small cell lung cancer (NSCLC) constitutes approximately 80–85% of cancer-related fatalities globally, and direct and indirect comparisons of various therapies for NSCLC are lacking. In this study, we aimed to compare the efficacy and safety of immune checkpoint inhibitors (ICIs) in...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Lin Zhu, Wenjuan He, Cunlei Xie, Yang Shu, Chunxia Zhang, Yawen Zhu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2024-12-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	treatment strategy immunotherapy overall survival progression-free survival adverse events
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1512468/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!